Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PMN

ProMIS Neurosciences (PMN)

ProMIS Neurosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PMN
DateTimeSourceHeadlineSymbolCompany
15/06/202406:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMNProMIS Neurosciences Inc
15/05/202406:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMNProMIS Neurosciences Inc
15/05/202406:01GlobeNewswire Inc.ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:PMNProMIS Neurosciences Inc
30/04/202421:00GlobeNewswire Inc.ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed AntibodiesNASDAQ:PMNProMIS Neurosciences Inc
09/04/202421:00GlobeNewswire Inc.ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSNASDAQ:PMNProMIS Neurosciences Inc
04/04/202422:00GlobeNewswire Inc.ProMIS Neurosciences to Present in Upcoming Investor Conferences in April NASDAQ:PMNProMIS Neurosciences Inc
02/04/202407:15GlobeNewswire Inc.ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsNASDAQ:PMNProMIS Neurosciences Inc
11/03/202422:00GlobeNewswire Inc.ProMIS Neurosciences Strengthens Global Intellectual Property PortfolioNASDAQ:PMNProMIS Neurosciences Inc
22/02/202423:00GlobeNewswire Inc.ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:PMNProMIS Neurosciences Inc
22/01/202423:00GlobeNewswire Inc.ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein VaccineNASDAQ:PMNProMIS Neurosciences Inc
08/01/202423:00GlobeNewswire Inc.ProMIS Neurosciences Issues Letter to ShareholdersNASDAQ:PMNProMIS Neurosciences Inc
03/01/202423:00GlobeNewswire Inc.ProMIS Neurosciences, Inc. Announces Leadership TransitionNASDAQ:PMNProMIS Neurosciences Inc
20/12/202323:00GlobeNewswire Inc.ProMIS Neurosciences Announces Publication on Novel Target for ALSNASDAQ:PMNProMIS Neurosciences Inc
20/11/202323:00GlobeNewswire Inc.ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s DiseaseNASDAQ:PMNProMIS Neurosciences Inc
15/11/202308:30GlobeNewswire Inc.ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:PMNProMIS Neurosciences Inc
08/09/202321:00GlobeNewswire Inc.ProMIS Neurosciences Closes $20.4 Million Private Placement FinancingNASDAQ:PMNProMIS Neurosciences Inc
07/09/202302:18GlobeNewswire Inc.ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PMNProMIS Neurosciences Inc
22/08/202306:12GlobeNewswire Inc.ProMIS Neurosciences Announces $20.4 Million Private Placement FinancingNASDAQ:PMNProMIS Neurosciences Inc
15/08/202307:33GlobeNewswire Inc.ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent HighlightsNASDAQ:PMNProMIS Neurosciences Inc
17/07/202321:00GlobeNewswire Inc.ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s PipelineNASDAQ:PMNProMIS Neurosciences Inc
14/07/202321:45GlobeNewswire Inc.ProMIS Announces Completion of ContinuanceNASDAQ:PMNProMIS Neurosciences Inc
10/07/202321:55GlobeNewswire Inc.ProMIS Neurosciences to Consolidate Trading on the Nasdaq ExchangeNASDAQ:PMNProMIS Neurosciences Inc
30/06/202322:00GlobeNewswire Inc.ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions ApprovedNASDAQ:PMNProMIS Neurosciences Inc
29/06/202322:00GlobeNewswire Inc.CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern TimeNASDAQ:PMNProMIS Neurosciences Inc
16/05/202307:00GlobeNewswire Inc.ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsNASDAQ:PMNProMIS Neurosciences Inc
08/05/202323:00GlobeNewswire Inc.ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s DiseaseNASDAQ:PMNProMIS Neurosciences Inc
26/04/202307:00GlobeNewswire Inc.Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s DiseaseNASDAQ:PMNProMIS Neurosciences Inc
24/04/202321:30GlobeNewswire Inc.ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual MeetingNASDAQ:PMNProMIS Neurosciences Inc
10/04/202321:30GlobeNewswire Inc.ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310NASDAQ:PMNProMIS Neurosciences Inc
29/03/202323:30GlobeNewswire Inc.Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023NASDAQ:PMNProMIS Neurosciences Inc
 Showing the most relevant articles for your search:NASDAQ:PMN